Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Expanded access in North America
Prostatic Neoplasms, Castration-Resistant
In this heavily pretreated EAP population with progressive mCRPC, enzalutamide was well tolerated and the safety profile was consistent with that of the AFFIRM trial.
PubMed Central ID
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency